How to Buy Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics.
Acadia Pharmaceuticals stock last closed at $20.68, down 6.76% from the previous day, and has decreased 2.5% in one year. It has overperformed other stocks in the Biotechnology industry by 0.19 percentage points. Acadia Pharmaceuticals stock is currently +5.03% from its 52-week low of $19.69, and -33.2% from its 52-week high of $30.96.
As of Sep 25, 2026, there are 172.31M shares of ACAD outstanding. The market cap of ACAD is $3.56B. In the last 24 hours, 3.36M ACAD shares were traded.
How to Buy Acadia Pharmaceuticals Stock
Not sure how to invest in Acadia Pharmaceuticals stock? Here's how.
- Decide where to buy Acadia Pharmaceuticals stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Acadia Pharmaceuticals stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Choose your payment method and add your details.
- Analyze Acadia Pharmaceuticals stock: The Acadia Pharmaceuticals ticker symbol is ACAD. Is Acadia Pharmaceuticals stock a good investment? Should you buy shares of ACAD? How do ACAD's underlying business fundamentals look? Do top analysts think Acadia Pharmaceuticals is a good buy? Why has ACAD's stock price moved recently? (Hint: Our stock market research tools can help you decide if ACAD is a good stock to buy).
- Place your ACAD buy order: Decide if you will purchase ACAD shares at the current market price or use a limit order to purchase ACAD stock at a given price.
- Get updates on your investment in ACAD: Create a watchlist to get live updates on your position in Acadia Pharmaceuticals stock.
Step 1: Decide where to buy Acadia Pharmaceuticals stock
You need a brokerage account in order to access the NASDAQ market and buy ACAD stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Technology to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal info so you can buy ACAD today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to open your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've opened your account on a good stock buying app, your next step is to transfer the money for your investment:
Watch this video walkthrough if you need help depositing money into your new brokerage account.
Step 4: Analyze Acadia Pharmaceuticals stock
Once you have identified the best place to buy Acadia Pharmaceuticals stock, it's critical to research their stock prior to investing, so you actually understand the risk and upside.
Acadia Pharmaceuticals stock quick numbers
Acadia Pharmaceuticals Overview
WallStreetZen was built to help everyday investors do better fundamental analysis in less time.
You can view all of the due diligence checks on ACAD's stock page.
What is the fair value of ACAD stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ACAD's true value.
Using relative valuations measures:
- ACAD could be undervalued based on its P/E ratio of 9.19x, relative to Biotechnology industry P/E ratio of 14.87x
- ACAD could be undervalued based on its P/B ratio of 2.73x, relative to Biotechnology industry P/B ratio of 5.19x
You can access additional valuation research on ACAD's stock here.
ACAD Financial Overview
Positive Financial Indicators:
- ACAD earnings of $121.37M is not enough to cover its interest payments.
- There are more short-term assets than short-term liabilities on the ACAD balance sheet.
- There are more short-term assets than long-term liabilities on the ACAD balance sheet.
- ACAD's operating cash flow of $160.32M allows it to safely service it's debt of $59.55M.
- ACAD profit margin has gone up from 21.8% to 33.4% in the past year.
- ACAD has a low debt to equity ratio of 0.33.
Negative Financial Indicators:
- Total ACAD debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Acadia Pharmaceuticals stock, according to Wall Street analysts?
Out of 13 sell side analysts who give forecasts on ACAD, the consensus analyst rating on Acadia Pharmaceuticals is a Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest ACAD Analyst Forecasts
Yigal Nochomovitz, a top 7% analyst from Citigroup maintains ACAD with a strong buy rating and lowers their ACAD price target from $40.00 to $33.00, on Sep 24, 2026.
Jeffrey Hung, a top 7% analyst from Morgan Stanley maintains ACAD with a hold rating and raises their ACAD price target from $27.00 to $28.00, on Aug 25, 2026.
Ashwani Verma, a top 11% analyst from UBS maintains ACAD with a strong buy rating and raises their ACAD price target from $45.00 to $49.00, on Aug 17, 2026.
UBS's Ashwani Verma raised their price target on Acadia Pharmaceuticals (NASDAQ: ACAD) by 8.9% from $45 to $49 on 2026/08/17. The analyst maintained their Strong Buy rating on the stock.
Acadia Pharmaceuticals reported its Q2 2026 earnings.
With a success probability of 50% and risk-adjusted peak sales of $1.6B, up from $1.3B, Acadia Pharmaceuticals is a promising investment ahead of remlifanserin's first ADP readout in 2026/09 or 2026/10, Verma told readers.
Earnings Report
For Q2 2026, Acadia Pharmaceuticals reported:
- EPS of $0.18, which beat the Zacks Consensus Estimate of $0.06 and, by 12.5%, Q2 2025’s $0.16.
- Revenue of $307.96M, which beat the Zacks Consensus Estimate by 4.81% and, by 16%, Q2 2025’s $264.57M.
For FY 2026, management guided:
- Revenue of $1.24B to $1.30B.
CEO Catherine Owen Adams commented: “Acadia delivered an outstanding Q2, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% Y/Y on an adjusted basis.
“For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance.
“For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field.
“We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7B in annual net sales in 2028.
“Looking ahead, we are excited about the anticipated topline results from our Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis in the 2026/09 to 2026/10 timeframe, which we believe represents a potentially transformational opportunity for Acadia.”
Matthew Hershenhorn, a top 50% analyst from Oppenheimer maintains ACAD with a hold rating and raises their ACAD price target from $23.00 to $25.00, on Aug 5, 2026.
Brian Abrahams, a top 14% analyst from RBC Capital maintains ACAD with a buy rating and raises their ACAD price target from $36.00 to $37.00, on Aug 5, 2026.
You can dig deeper into what analysts are forecasting on the Acadia Pharmaceuticals stock forecast page.
ACAD Trading Indicators
ACAD Performance Numbers
Last year, ACAD earnings were $380.48M. In the last 2 year, ACAD's earnings have grown by 253.55% per year. This was faster than the Biotechnology industry average of 9.76%.
Last year, ACAD revenue was $1.14B. In the last 5 year, ACAD's revenue has increased by 19.7% per year. This was slower than the Biotechnology industry average of 31.98%.
Learn more about ACAD's earnings and revenue performance here.
Who is buying/selling ACAD?
Over the last year, executives and large shareholders at ACAD have sold more shares than they have bought.
Mark C. Schneyer, CFO;EVP of ACAD, was the latest ACAD insider to buy. They bought $254,969.28 worth of ACAD stock on Aug 6, 2026.
Learn more about who owns ACAD stock here.
Can I rely on ACAD as an income stream?
No, Acadia Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about ACAD
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your ACAD buy order
There are two main options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually fine. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a given dollar amount, place a limit order.
Press the Open Trade button and your broker will execute the order.
If you need additional info about investing in stocks on eToro, watch the helpful video below:
Step 6: Get updates on your investment in ACAD
Now that you own some ACAD shares, you'll want to stay up-to-date on your new investment.
Add ACAD to a watchlist to monitor your ACAD stock.
ACAD Feed
How to Buy Stock in Acadia Pharmaceuticals
To summarize, here are the 6 steps for buying Acadia Pharmaceuticals stock:
- Decide where to buy Acadia Pharmaceuticals stock
- Open a brokerage account
- Put funds into your investment account
- Analyze Acadia Pharmaceuticals stock
- Place your ACAD buy order
- Get updates on your investment in ACAD
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your new investment in Acadia Pharmaceuticals, hit the button below to create your watchlist.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.